Navigation Links
Cancer-Causing Gene Discovery Suggests New Therapies
Date:1/23/2009

to changes in protein levels of a key gene that is essential for normal distribution of genetic material between daughter cells during cell division."

The findings are a positive step, he emphasizes, because they suggest that halting Myc's action on protein production with targeted therapies could prevent harmful genetic changes in cells that lead to cancer progression.

Co-authors with Ruggero and Barna are Aya Pusic, BS, scientific research assistant; Ornella Zollo,PhD, and Maria Costa, PhD, postdoctoral fellows, and Nadya Kondrashov, BA, all at UCSF; Eduardo Rego at the Center for Cell Based Therapy, Fundacao Hemocentro de Rebeiaro Preto, Sao Paulo, Brazil; and Pulivarthi Rao in the Department of Pediatrics, Baylor College of Medicine.

The research was funded by the National institutes of Health and the Sandler Foundation.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.


###

Read the full story at http://www.prweb.com/releases/UCSF/Discovery/prweb1906964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
2. Zassi Medical Evolutions Launches New Online Company That Uses Business DNA to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry
3. American Asthma Foundation Announces Breakthrough Discovery
4. Life Sciences Discovery awards health research program grants
5. MaxCyte Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery - LIVE Q&A to Follow
6. Exciting discovery could stop cancer from killing people
7. Discovery Healths NATIONAL BODY CHALLENGE Weighs in for a Sixth Season, Urging Americans to Break up With Bad Habits
8. Surprise discovery made in cancer research
9. Med school discovery could lead to better cancer diagnosis, drugs
10. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
11. Leeds researchers reshape the future of drug discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer-Causing Gene Discovery Suggests New Therapies
(Date:7/29/2014)... (PRWEB) July 29, 2014 Helping people ... an immensely complex challenge that requires deep knowledge of ... to improve therapeutic options and outcomes has been the ... of biomedical engineering, since he joined the NJIT faculty ... significance is underscored by substantial funding from sources such ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Successful negotiations may depend ... with wider faces may have an advantage, according to a ... broader face are more successful when negotiating for themselves than ... may not be an asset when negotiations require collaboration and ... we think about it or not. It,s not just the ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Bowers, PhD, RN, FAAN, of the University of Wisconsin-Madison ... Minority Issues in Gerontology Outstanding Mentorship Award. , This ... has exemplified outstanding commitment and dedication to mentoring minority ... presentation will take place at GSA,s 67th Annual Scientific ...
(Date:7/29/2014)... More Zeppelin than Zen, the Rock Spa® at ... having a complete renovation and, upon its re-opening in the ... and soul. , The Rock Spa® will include an all-new ... for experienced hair and nail stylists. Both part time and ... will be given full medical and health benefits, a rare ...
(Date:7/29/2014)... Oneida Nation Homelands, NY (PRWEB) July 29, 2014 ... Oneida Indian Nation have sent a letter to Washington NFL ... team representatives that opposition to the R-word racial slur is ... To date, the team and Snyder have yet to respond. ... to release the full text of the letter, which was ...
Breaking Medicine News(10 mins):Health News:Continuing the Quest for Better Stroke Therapies 2Health News:Continuing the Quest for Better Stroke Therapies 3Health News:Continuing the Quest for Better Stroke Therapies 4Health News:Wider Face May Give You an Edge in Negotiations 2Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Rock Spa® at Seminole Hard Rock Hotel & Casino Tampa Prepares for Expansion 2Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2
... 21 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, ... has closed its previously announced public offering (the ... $12.65 million. , The Company issued 73,333,333 Units ... "Offering Price"). The Company concurrently issued an additional ...
... Couples using assisted reproductive technology should be made aware, ... -- Compared to naturally conceived twins, those conceived through ... hospitalized and admitted to neonatal intensive care, finds a ... for all twins born in Western Australia between 1994 ...
... New White Paper Outlines Possible Ways to Improve ... Today, during a Partnership to Fight Chronic ... researchers Michael J. O,Grady, Ph.D., and James C. ... Projections for Diabetes and other Chronic Diseases: The ...
... Indicator of Demand for Well-Priced New and Refurbished ... Despite numerous negative earnings announcements, the demand ... to be robust during the current economic downturn. ... refurbished ultrasound solutions, reported a 118 percent increase ...
... May 21 CPC of America, Inc. (OTC Bulletin ... patent of a synthetic sealant for specific application to ... development and testing of the MedClose(TM) VCS, which is ... diagnostic and interventional procedures. In addition, CPC is ...
... May 21 Genomic Health, Inc. (Nasdaq: ... results from three studies at the American Society of ... - June 2, 2009, at the Orange County Convention ... widely-adopted Onco type DX(R) breast cancer test, which ...
Cached Medicine News:Health News:Response Biomedical Closes $12.65 million Unit Offering 2Health News:Response Biomedical Closes $12.65 million Unit Offering 3Health News:Response Biomedical Closes $12.65 million Unit Offering 4Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... July 29, 2014   ... will present data from a Phase I clinical ... slow or stop Parkinson,s disease progression. The Michael J. ... grant and will discuss the impact of the results ... When:   Thursday, July 31, 2014     ...
(Date:7/29/2014)... Calif. , July 29, 2014  Drug ... amplified with rising incidence rates and the intense ... a preventative vaccine. Change is underway as the ... regimens towards highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... September 24 , - Novel Treatment ... and Reduction in Depressive Symptoms, Positive ... today at the 8th,European Congress of Epileptology, ... a novel once daily,anti-epileptic agent, significantly reduced ...
... Oral Insulin Capsule, ... on Type 1 Diabetics, JERUSALEM, Israel, September ... delivery systems, announced today that it has commenced Phase 2A,studies of ORMD ... Medical Center in Jerusalem, Israel., Oramed,s Phase 2A trial is focused ...
Cached Medicine Technology:New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 2New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 3New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 4New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 5New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 6Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
Medicine Products: